CytoDyn (CYDY) Accumulated Expenses (2011 - 2026)

CytoDyn's Accumulated Expenses history runs 15 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• Quarterly Accumulated Expenses rose 5145.54% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $11.8 million (up 5145.54% YoY) and the FY2025 annual result came in at $18.2 million, up 8626.44% from the prior year.
• Accumulated Expenses was $11.8 million for Q1 2026 at CytoDyn, down from $16.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $18.2 million in Q2 2025 and bottomed at $111000.0 in Q4 2024.
• A 5-year average of $4.0 million and a median of $496000.0 in 2022 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 14764.86% in 2025, while the deepest fall reached 98.41% in 2025.
• CytoDyn's Accumulated Expenses stood at $496000.0 in 2022, then slumped by 54.03% to $228000.0 in 2023, then tumbled by 51.32% to $111000.0 in 2024, then soared by 14764.86% to $16.5 million in 2025, then declined by 28.79% to $11.8 million in 2026.
• Business Quant data shows CYDY's Accumulated Expenses at $11.8 million in Q1 2026, $16.5 million in Q4 2025, and $236000.0 in Q3 2025.